Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 1, Pages 97-109Publisher
SPRINGER
DOI: 10.1007/s00280-014-2621-7
Keywords
Pan-HER inhibitor; Population pharmacokinetics; NONMEM; Cancer; Modeling and simulation; HM781-36; Poziotinib
Categories
Funding
- Hanmi Pharm., Co. Ltd., Seoul, Korea
Ask authors/readers for more resources
To develop a population pharmacokinetic (PK) model for HM781-36 (poziotinib) and its metabolites in cancer patients. Blood samples were collected from three phase I studies in which fifty-two patients received oral HM781-36B tablets (0.5-32 mg) once daily for 2 weeks, and another 20 patients received oral HM781-36B tablets (12, 16, 18, 24 mg) in fasting (12 patients) or fed (eight patients) state once daily for 4 weeks. Nonlinear mixed effect modeling was employed to develop the population pharmacokinetic model. HM781-36 PK was ascribed to a two-compartment model and HM781-36-M1/-M2 PK to one-compartment model. HM781-36 oral absorption was characterized by first-order input (absorption rate constant: 1.45 +/- A 0.23 h(-1)). The central volume of distribution (185 +/- A 12.7 L) was influenced significantly by body weight. The absorption rate constant was influenced by food. The typical HM781-36 apparent clearance was 34.5 L/h (29.4 %CV), with an apparent peripheral volume of distribution of 164 L (53.5 %CV). Other covariates did not significantly further explain the PKs of HM781-36. The proposed model suggests that HM781-36 PKs are consistent across most solid tumor types, and that the absorption process of HM781-36 is affected by the fed state before dosing. HM781-36 PKs are not complicated by patient factors, other than body weight.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available